L’INESSS in Québec is evaluating inotersen (Tegsedi – Akcea Therapeutics Canada) a treatment for adults with hATTR amyloidosis polyneuropathy. L’INESSS does this evaluation to determine whether to recommend the drug for reimbursement by the Québec government. Patients, parents and caregivers can provide their opinion by completing this questionnaire by March 25, 2019: https://www.inesss.qc.ca/index.php?id=639&L=1. If you need help doing this, please contact:info@rqmo.org

Share This